Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Winton Gibbons, Bill Moffitt, Rollie Carlson, Matt Winkler

Premium

Nanosphere said in recent filings with the US Securities and Exchange Commission that Winton Gibbons will resign from his role as senior vice president of business development at the end of April, and that Bill Moffitt will continue to serve as president and CEO under a new agreement that runs through 2013. The agreement provides Moffitt with a base salary of $458,000 with a possible bonus of up to $275,000. Nanosphere said it has no plans to refill Gibbons' position when he departs.


Asuragen said this week that Rollie Carlson has been appointed president and CEO. Carlson has served as the company's president and chief operating officer. Outgoing CEO Matt Winkler will continue to be chairman of the Austin, Texas-based company, as well as its chief scientific officer.

Carlson has been president of Asuragen since 2006. Prior to joining Asuragen, he held several positions at Abbott Laboratories, including vice president and general manager of the Vysis molecular diagnostic business.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.